Only one drug (sorafenib) is approved for the treatment of advanced hepatocellular carcinoma (HCC), but alternatives are urgently needed. The safety of nivolumab (PD-1 immune checkpoint inhibitor) was tested in a phase I/II, open-label, dose escalation and expansion trial (CheckMate 040), in patients with or without viral hepatitis and as first-line or second-line (after sorafenib) therapy. Nivolumab had a manageable safety profile, with acceptable tolerability. Moreover, the objective response rates (range 15–20%) combined with the substantial reductions in tumour burden indicated the potential of nivolumab as HCC therapy. Results of the ongoing phase III trial for nivolumab versus sorafenib in advanced HCC are awaited.
References
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)31046-2 (2017)
Rights and permissions
About this article
Cite this article
Ray, K. Nivolumab: checkmate for hepatocellular carcinoma?. Nat Rev Gastroenterol Hepatol 14, 326 (2017). https://doi.org/10.1038/nrgastro.2017.62
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.62
This article is cited by
-
A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients
Journal of Cancer Research and Clinical Oncology (2023)